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Abstract: OBJECTIVES We aimed at evaluating bacterial DNA (bactDNA) presence in blood of Crohn’s
disease (CD) patients in remission as an independent risk factor of flare at 6 months. METHODS This is
a prospective, multicenter study on CD patients with Crohn’s disease activity index (CDAI)<150. The
primary end point was time-to-relapse as evaluated by CDAI>150 in the following 6 months. BactDNA in
blood, the nucleotide-binding oligomerization domain containing 2 (NOD2) genotype, and serum cytokine
levels were determined at baseline. RESULTS A total of 288 patients were included. BactDNA was
detected in 98 patients (34.0%). A variant-NOD2 genotype was identified in 114 patients (39.6%).
Forty patients (14%) relapsed during follow-up. Multivariate survival analysis identified bactDNA as
an independent risk factor of flare (hazard ratio (HR) 8.75 (4.02-19.06) 95% confidence interval (CI)).
Hospitalization, surgery, switch of treatment, initiation and escalation of anti-tumor necrosis factor (TNF)
therapy, steroids initiation, and increased fecal calprotectin levels at 6 months were associated with
bactDNA at baseline. A logistic regression analysis showed bactDNA as an independent and significant
predictive factor of hospitalization (odds ratio (OR) 11.9 (3.4-42.3); P<0.001), steroids startup (OR 8.5
(2.7-27.1); P<0.001), and switch of treatment (OR 3.5 (1.6-7.7); P=0.002) at 6 months. No relationship
was observed between bactDNA and mucosal lesions in patients with colonoscopy at admission. Serum
pro-inflammatory cytokines were significantly increased in patients with bactDNA or a variant-NOD2
genotype. The combination of both factors induced decreased anti-TNF-￿ levels and a higher percentage
of patients on intensified anti-TNF therapy. CONCLUSIONS BactDNA is an independent risk factor of
relapse at 6 months in CD patients. BactDNA is also independently associated with an increased risk of
hospitalization, switch of treatment, and steroids initiation.
DOI: https://doi.org/10.1038/ajg.2016.8
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Abstract	  
	  
Background:	  Translocation	  of	  bacterial	  DNA	  (bactDNA)	  is	  a	  frequent	  event	  in	  patients	  with	  Crohn’s	  disease.	  We	  aimed	  at	  evaluating	  bactDNA	  presence	  in	  blood	  of	  CD	  patients	  in	  remission	  as	  an	  independent	  risk	  factor	  of	  flare	  at	  6	  months.	  	  
Methods:	   Prospective,	  multicenter	   study	  on	  CD	  patients	  with	  CDAI<150.	  The	  primary	  endpoint	   was	   time-­‐to-­‐relapse	   as	   evaluated	   by	   CDAI>150	   in	   the	   following	   6	   months.	  BactDNA	   in	   blood,	   the	  NOD2	   genotype	   and	   serum	   cytokine	   levels	  were	  determined	   at	  baseline.	  	  	  
Results:	  288	  patients	  were	   included.	  BactDNA	  was	  detected	   in	  98	  patients	   (34.0%).	  A	  variant-­‐NOD2	   genotype	  was	   identified	   in	   114	   patients	   (39.6%).	   Forty	   patients	   (14%)	  relapsed	   during	   follow-­‐up.	   Multivariate	   survival	   analysis	   identified	   bactDNA	   as	  independent	  risk	  factor	  of	  flare	  (HR	  8.75	  [4.02-­‐19.06]	  95%CI).	  Hospitalization,	  surgery,	  switch	  of	  treatment,	  initiation	  and	  escalation	  of	  anti-­‐TNF	  therapy,	  steroids	  initiation	  and	  increased	   fecal	   calprotectin	   levels	   at	   6	   months	   were	   associated	   with	   bactDNA	   at	  baseline.	   A	   logistic	   regression	   analysis	   showed	   bactDNA	   as	   an	   independent	   and	  significant	   predictive	   factor	   of	   hospitalization	   (OR	   11.9	   [3.4-­‐42.3];	   p<0.001),	   steroids	  startup	  (OR	  8.5	  [2.7-­‐27.1];	  p<0.001)	  and	  switch	  of	  treatment	  (OR	  3.5	  [1.6-­‐7.7];	  p=0.002)	  at	   6	  months.	   No	   relationship	  was	   observed	   between	   bactDNA	   and	  mucosal	   lesions	   in	  patients	   with	   colonoscopy	   at	   admission.	   Serum	   proinflammatory	   cytokines	   were	  signifcantly	   increased	   in	   patients	   with	   bactDNA	   or	   a	   variant-­‐NOD2	   genotype.	   The	  combination	   of	   both	   factors	   induced	   decreased	   anti-­‐TNF-­‐alpha	   levels	   and	   a	   higher	  percentage	  of	  patients	  on	  intensified	  anti-­‐TNF	  therapy.	  	  	  
Conclusion:	   BactDNA	   is	   an	   independent	   risk	   factor	   of	   relapse	   at	   6	   months	   in	   CD	  patients.	   BactDNA	   is	   also	   independently	   associated	   with	   an	   increased	   risk	   of	  hospitalization,	  switch	  of	  treatment	  and	  steroids	  initiation.	  	  	  	  
Keywords:	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Introduction	  	  The	   translocation	   of	   bacterial	   genomic	   fragments	   (bactDNA)	   into	   blood	   is	   a	   frequent	  event	   arising	   in	   up	   to	   40%	   of	   patients	   with	   Crohn’s	   disease	   1,	   2.	   The	   multifactorial	  etiology	   of	   the	   disease	   includes	   partial	   genetic	   susceptibility	   and	   immunological	  interactions	   between	   the	   host	   and	   commensal	   bacteria	   3-­‐6.	   An	   impaired	   host-­‐microbe	  immune	   relationship,	   probably	   driven	   by	   allelic	   variants	   in	   these	   predisposition-­‐associated	   genes,	   has	   been	   associated	   with	   the	   development	   of	   inflammatory	   bowel	  disease	  7	  and	  may	  contribute	  for	  the	  translocation	  of	  bacterial	  antigenic	  products,	  which	  in	  turn,	  are	  closely	  related	  to	  a	  sustained	  inflammatory	  response	  in	  CD	  patients	  8.	  	  	  BactDNA	   is	   a	   potent	   immunogenic	   bacterial	   product	   able	   to	   trigger	   a	  Th1-­‐biased	  pro-­‐inflammatory	  response	  through	  toll-­‐like	  receptor	  (TLR)-­‐9	  recognition	  and	  nuclear	  factor	  kappa-­‐B	   (NFk-­‐B)	   activation	   9-­‐12.	   Pro-­‐inflammatory	  mediators	   such	   as	   Tumor	   necrosis	  factor	   alpha	   (TNF-­‐α),	   interleukin	   (IL)-­‐6,	   IL-­‐12	   and	   Interferon	   gamma	   (IFN-­‐γ)	   are	  significantly	  increased	  in	  response	  to	  bactDNA	  13-­‐16	  and	  are	  also	  increased	  in	  active	  CD	  patients	  17-­‐20.	  On	  the	  other	  hand,	  we	  have	  previously	  shown	  that	  CD	  patients	  bearing	  a	  variant	   NOD2	   genotype	   have	   significantly	   decreased	   phagocytic	   and	   bactericidal	  activities,	  as	  well	  as	  increased	  serum	  TNF-­‐α	  levels	  in	  response	  to	  bactDNA	  8.	  Variants	  in	  this	  gene	  have	  been	  associated	  with	  predisposition	  to	  CD	  21-­‐24,	  the	  regulation	  of	  the	  gut	  immune	  response	  and	  microbiota	  25,	  26,	  and	  even	  disease	  complications	  27,	  28.	  	  	  Controlling	   the	   adverse	   effects	   of	   an	   exacerbated	   pro-­‐inflammatory	   reaction	   in	   CD	  patients	  is	  of	  great	  relevance	  for	  the	  course	  of	  disease.	  Continued	  flares	  due	  to	  failure	  of	  medical	   treatment,	   bowel	   obstruction,	   fistulae	   or	   abscess	   formation	   is	   associated,	  besides	  pain	  and	  discomfort	   in	  patients,	  with	  need	   for	  hospitalization	  and,	   eventually,	  surgery	   both	   in	   luminal	   and	   perianal	   disease	   29.	   Current	   therapies	   are	   aimed	   at	  preventing/reducing	  the	   inflammatory	  outbreaks	  and	  to	  maintain	  clinical	  remission	   in	  CD	  patients	  by	  targeting	  some	  of	  the	  cytokines	  mentioned	  above.	  BactDNA	  translocation,	  which	  deeply	   influences	   the	   cytokine	  network,	  may	   constitute	   a	  disrupting	   factor	   that	  imbalances	  therapeutic-­‐induced	  homeostasis	  in	  these	  patients,	   increasing	  their	  risk	  for	  relapse.	  	  
Thus,	   the	   aim	   of	   the	   present	   investigation	   has	   been	   to	   determine	   whether	   bactDNA	  presence	  in	  blood	  of	  CD	  patients	  in	  remission	  constitutes	  an	  independent	  risk	  factor	  of	  relapse	  and	  other	  complications	  in	  the	  short-­‐term,	  controlling	  the	  results	  by	  the	  NOD2	  gene	  status.	  	  	  	  	  	  	  	  	  	  	   	  
Patients	  and	  methods	  	  
Patients	  and	  study	  design.	  Consecutive	  patients	  diagnosed	  with	  Crohn’s	  disease	  and	  controlled	  at	  three	  hospitals	  in	  the	   area	   of	  Alicante,	   Spain,	  who	  were	   in	   remission,	   as	   determined	  by	  CDAI<150	  were	  included	   in	   this	  prospective,	  observational	  multicenter	  study.	  The	  diagnosis	  of	  CD	  was	  established	   according	   to	   standard	   clinical,	   endoscopic,	   histological	   and	   radiographical	  criteria	  30.	  Patients	  treated	  with	  antibiotics	  in	  the	  previous	  4	  weeks,	  patients	  with	  signs	  of	  active	   infection	  and	  those	  who	  refuse	  to	  sign	   informed	  consent	   to	  participate	   in	   the	  study	  were	  excluded.	  Twenty-­‐five	  healthy	  controls	  were	  included	  in	  the	  study	  of	  NOD2	  allelic	   variants	   distribution.	   The	   Ethics	   Committee	   of	   the	   each	   hospital	   approved	   the	  study	  protocol.	  	  Usual	  clinical	  and	  analytical	  variables	  in	  the	  management	  of	  CD	  patients	  were	  recorded.	  All	  patients	  were	  Caucasian	  of	  Mediterranean	  ethnicity	  and	  were	  classified	  according	  to	  the	  Montreal	  classification	  31.	  All	  included	  patients	  received	  diaries	  to	  record	  symptoms	  1	   week	   prior	   to	   inclusion	   and	   sample	   collection.	   Therapies	   were	   grouped	   in	   four	  categories:	  No	   immunosuppressors	   (IS)/no	  anti-­‐TNF,	  which	   included	  patients	  without	  any	  treatment	  and	  those	  on	  mesalazine;	  IS	  (patients	  on	  azathioprine	  or	  methotrexate),	  anti-­‐TNF	  (patients	  on	   infliximab	  or	  adalimumab),	  and	  the	  combination	  of	   IS	  with	  anti-­‐TNF.	   Anti-­‐TNF	   intensified	   therapy	   was	   defined	   either	   by	   an	   increased	   dose	   or	   an	  increase	  in	  the	  frequency	  of	  infusions	  versus	  dosing	  or	  schedule	  upon	  start	  of	  treatment.	  	  Blood	   samples	   were	   obtained	   for	   routine	   haematological	   and	   biochemical	   studies	   at	  inclusion	   and	   inoculated	   in	   aerobic	   and	   anaerobic	   blood	   culture	   bottles,	   10	   ml	   each.	  Simultaneously,	   two	  separate	  blood	  samples	  were	   inoculated	  under	  aseptic	  conditions	  in	  rubber-­‐sealed	  sterile	  Vacutainer	  SST	  II	  and	  K3E	  tubes,	  respectively	  (BD	  Diagnostics,	  Erembodegem,	  Belgium)	  that	  were	  never	  exposed	  to	  free	  air.	  	  Patients	   were	   followed	   up	   for	   6	   months.	   The	   study’s	   primary	   endpoint	   was	   time	   to	  relapse	  as	  evaluated	  by	  CDAI>150,	  or	  by	  clinical	  symptoms	  and	  endoscopic	  findings	  or	  fecal	   calprotectin>250ug/g	   in	   patients	  with	   previous	   surgery.	   Secondary	   endpoints	   in	  
the	   follow-­‐up	   timeframe	  were	   the	   incidence	  of	   complications	   such	   as	  hospitalizations,	  switch	  of	  treatment,	  anti-­‐TNF	  intensification,	  surgery	  or	  initiation	  of	  steroids.	  	  
Identification	  of	  bactDNA	  fragments	  and	  NOD2	  genotyping.	  	  Genomic	  DNA	  was	  isolated	  from	  5x106	  cells	  with	  the	  QIAmp	  DNA	  Blood	  Minikit	  (Qiagen,	  Hilden,	   Germany).	   BactDNA	   was	   identified	   by	   running	   a	   broad-­‐range	   PCR	   with	   5'-­‐AGAGTTTGATCATGGCTCAG-­‐3'	   as	   forward	   and	   5'-­‐ACCGCGACTGCTGCTGGCAC-­‐3'	   as	  reverse	   primers,	   followed	   by	   partial	   nucleotide	   sequencing	   of	   a	   conserved	   region	   of	  16SrRNA	   gene.	   The	   tree	   common	   NOD2/CARD15	   allelic	   variants	   at	   SNP-­‐8	   (R702W,	  rs2066844),	   SNP-­‐12	   (G908R,	   rs2066845)	   and	   SNP-­‐13	   (L1007finsC,	   rs2066847)	   were	  genotyped	   by	   TaqMan	   technology	   (Applied	   Biosystems)	   using	   commercially	   available	  TaqMan	  SNP	  Genotyping	  Assays	  and	  TaqMan	  Genotyping	  Master	  Mix	  on	  a	  7900HT	  Fast	  Real-­‐Time	   PCR	   System	   using	   SDS	   2.2	   Software	   (Applied	   Biosystems),	   as	   previously	  described	  8.	  A	  variant	  NOD2	  genotype	  was	  defined	  as	  carrying	  any	  of	  the	  three	  studied	  variants	   either	   in	   homozygosis	   or	   heterozygosis.	   To	   minimize	   error,	   all	   genotyping	  results	  were	  scored	  twice	  and	  the	  second	  assessor	  was	  not	  aware	  either	  of	  each	  patient	  disease-­‐status	  or	  the	  first	  genotype	  results.	  No	  missing	  genotypes	  were	  present.	  	  
Serum	  cytokine	  and	  free	  anti-­‐TNF-­‐α	  levels.	  Presence	  of	  anti-­‐drug	  antibodies.	  Serum	   TNF-­‐α,	   IFN-­‐γ,	   IL-­‐12p40	   levels	   were	   determined	   by	   flow	   cytometry	   using	  Cytometric	   Bead	   Arrays	   (CBA)	   in	   a	   FACs	   Canto	   II	   (Becton	   Dickinson,	   San	   Jose,	   CA).	  Enzyme-­‐linked	   immunosorbent	   assays	   (ELISAs)	   were	   carried	   out	   to	   measure	   free	  infliximab	   and	   adalimumab	   levels	   and	   to	   detect	   anti-­‐drug	   antibodies	   (Matriks	   Biotek,	  Ankara,	  Turkey)	  according	  to	   the	  manufacturers’	   instructions.	  All	  samples	  were	   tested	  in	  triplicate	  and	  read	   in	  a	  Sunrise	  Microplate	  Reader	  (Tecan,	  Männedorf,	  Switzerland).	  The	  detection	  limit	  for	  each	  cytokine	  assay	  varied	  between	  2–5	  pg/mL	  and	  between	  10-­‐30ng/mL	  in	  the	  case	  of	  free	  anti-­‐TNF-­‐α	  kits.	  Standard	  curves	  were	  generated	  for	  every	  plate	  and	  the	  average	  zero	  standard	  optical	  densities	  were	  subtracted	  from	  the	  rest	  of	  the	  standards	  and	  samples	  to	  obtain	  a	  corrected	  concentration	  for	  all	  parameters.	  The	  presence	   of	   anti-­‐drug	   antibodies	   was	   evaluated	   by	   a	   cut-­‐off	   value	   estimated	   by	  multiplying	   the	   optical	   density	   (OD)	   of	   the	   zero	   standard	   by	   3,	   as	   indicated	   by	   the	  manufacturers.	   Samples	   were	   considered	   positive	   when	   the	   ratio	   sample	   OD/zero	  standard	  OD	  was	  higher	  than	  3.	  	  	  
	  	  
Statistical	  analysis.	  Continuous	  variables	  were	   reported	  as	  mean	  ±	   standard	  deviation	  or	  95%	  confidence	  interval,	  and	  categorical	  variables	  were	  expressed	  as	  frequencies	  and	  percentages.	  In	  a	  first	  univariate	  analysis,	  differences	  between	  patient	  groups	  were	  analyzed	  using	  the	  U-­‐Mann	  Whitney	  test	  for	  quantitative	  data	  and	  Chi-­‐square	  test	  for	  qualitative	  data.	  Time	  to	  relapse	   was	   analyzed	   using	   a	   Kaplan-­‐Meier	   survival	   approach	   and	   log-­‐rank	   test	  according	   to	   bactDNA	   and	   group	   of	   therapy	   (NOD2/CARD15	   mutations	   status).	   A	  multivariate	  Cox	  proportional	  regression	  analyses	  to	  study	  factors	  significantly	  related	  to	   time	   to	   relapse	   was	   performed	   in	   two	   steps:	   first,	   an	   univariate	   analyses	   using	  bactDNA,	  NOD2	  genotype,	  groups	  of	  therapy	  and	  clinical	  and	  demographic	  variables	  as	  independent	   variables	   and	   then	   variables	   showing	   a	   p	   value	   lower	   than	   0.1	   were	  considered	   in	   a	   multivariate	   analysis.	   The	   associations	   between	   clinical	   and	  demographic	   data	   and	   secondary	   outcomes	   with	   at	   least	   10	   events	   each	   as	  hospitalization,	  switch	  of	  treatment	  and	  the	  startup	  of	  steroids	  during	  the	  study	  follow-­‐up	  were	  evaluated	  using	  a	  multiple	  logistic	  regression	  analysis	  when	  time	  to	  event	  was	  not	  available.	  Statistical	  significance	  was	  considered	  at	  p	  values	  less	  than	  0.05.	  Statistical	  analysis	  was	  performed	  using	  SPSS	  v15	  and	  R	  software.	  	  
Results	  
	  
Characteristics	  of	  patients.	  A	  total	  series	  of	  288	  consecutive	  patients	  fulfilling	  inclusion	  and	  exclusion	  criteria	  were	  included	   from	   2012	   to	   2014.	   All	   patients	   completed	   the	   6-­‐month	   follow-­‐up	   period.	  Clinical	  and	  analytical	  characteristics	  of	  the	  study	  cohort	  are	  shown	  in	  Table	  1.	  Briefly,	  mean	  age	  was	  42±15	  years	  and	  53%	  were	  male.	  Mean	  CDAI	  was	  62.6±33.1	  and	  mean	  fecal	  calprotectin	  was	  79.5±91.7	  µg/g.	  Forty	  percent	  of	  the	  study	  population	  were	  active	  smokers	  and	  25%	  had	  a	  history	  of	  previous	  surgery.	  	  Ileal	  disease	  was	  present	  in	  45%	  of	  patients	  whereas	  colonic	  or	  ileo-­‐colonic	  disease	  was	  present	  in	  50%	  of	  patients.	  Twenty-­‐one	   percent	   of	   patients	   presented	   with	   perianal	   disease.	   Regarding	   therapies	   at	  inclusion,	  28%	  of	  patients	  were	  on	  anti-­‐TNF,	  either	  alone	  or	  combined,	  and	  55%	  were	  receiving	  immunosuppressors.	  	  	  
Bacterial	  DNA	  translocation	  and	  NOD2	  allelic	  variant	  distribution	  in	  CD	  patients	  	  BactDNA	   was	   detected	   in	   blood	   samples	   from	   98	   CD	   patients	   in	   remission	   (34.0%).	  Partial	  sequencing	  analysis	  identified	  23	  species	  that	  are	  resumed	  in	  Table	  2.	  As	  can	  be	  observed,	  77.6%	  of	  identified	  bactDNA	  belonged	  to	  the	  Enterobacteriaceae	  family	  and	  	  E.	  
coli	  was	   the	   mainly	   identified	   species	   among	   bactDNA-­‐positive	   CD	   patients	   (38.7%).	  BactDNA	  from	  gram-­‐positive	  microorganisms	  was	  detected	  in	  22.4%	  of	  CD	  patients	  with	  bacterial	  translocation.	  	  The	  amount	  of	  amplified	  bactDNA	  was	  not	  significantly	  different	  between	  species,	  family	  or	  gram	  distribution.	  	  
	  The	   distribution	   of	   patients	   according	   to	   the	   presence	   of	   bactDNA	   in	   blood	   can	   be	  followed	   in	   Table	   1.	   No	   significant	   baseline	   clinical	   or	   analytical	   differences	   were	  observed	  between	  patients	  according	  to	  bactDNA	  translocation,	  including	  the	  groups	  of	  therapy.	  	  	  A	   variant	   NOD2	   genotype	   was	   identified	   in	   114	   patients	   (39.6%).	   Distribution	   of	  genotypes	  and	  allelic	  frequencies	  in	  CD	  patients	  is	  shown	  in	  Supplementary	  Table	  1.	  All	  variants	  were	  found	  to	  be	  in	  the	  Hardy–Weinberg	  equilibrium	  in	  the	  controls.	  BactDNA	  was	  present	   in	  37	  patients	  with	  a	  wild	   type	  NOD2	  genotype	  and	   in	  61	  patients	  with	  a	  variant	  NOD2	  genotype	  (32.5%	  vs	  35%,	  respectively;	  p=ns).	  There	  were	  no	  significant	  
differences	   either	   in	   any	   of	   the	   studied	  NOD2	   variant	   allelic	   frequencies	   according	   to	  bactDNA	  patients’	  distribution.	  	  	  	  
Evaluation	  of	  relapse	  during	  the	  following	  6	  months	  according	  to	  the	  presence	  of	  bactDNA.	  Forty	  CD	  patients	   (14%)	  out	  of	   the	  overall	   series	  of	  patients	   included	  relapsed	  during	  the	   study	   follow-­‐up	   period.	   Thirty-­‐two	   patients	   out	   of	   98	  with	   bactDNA	   fragments	   in	  blood	  (33%)	  vs	  8	  patients	  out	  of	  190	  without	  bactDNA	  (4%,	  p=0.001)	  presented	  a	  flare-­‐up.	  Relapse	  during	   follow-­‐up	  was	  also	  significantly	  different	  according	   to	   the	  group	  of	  therapy	   (no	   IS/no	   anti-­‐TNF	   14.4%;	   IS	   12.4%;	   anti-­‐TNF	   18%;	   IS	   +	   anti-­‐TNF	   32.3%,	  p=0.004).	  No	  other	  baseline	  characteristics	  of	  patients	  were	  different	  when	  considering	  relapse	   at	   6	   months.	   Interestingly,	   16	   wild-­‐type	   NOD2	   (14%)	   and	   24	   variant	   NOD2	  (13.8%)	   genotyped	   patients	   relapsed	   during	   the	   study	   follow-­‐up,	   without	   significant	  differences	  in	  the	  frequency	  of	  studied	  allelic	  variants.	  	  	  The	  survival	  analysis	  of	  time	  to	  first	  relapse	  according	  to	  bactDNA	  presence	  in	  blood	  and	  to	  the	  group	  of	  therapy	  is	  shown	  in	  Figure	  1.	  In	  the	  Cox	  proportional	  hazards	  multiple	  regression	   analysis,	   both	   variables	   remained	   independently	   significant,	   as	   can	   be	  followed	   in	   Table	   3.	   There	   was	   a	   significant	   difference	   in	   the	   relapse	   rate	   between	  patients	   on	   IS	   combined	  with	   anti-­‐TNF	   compared	  with	   patients	   on	   no	   IS/no	   anti-­‐TNF	  (p=0.002).	  
	  
Clinical	  evolution	  of	  patients	  Nineteen	   patients	   (6.7%)	   of	   the	   overall	   series	   of	   patients	   included	   required	  hospitalization	   during	   the	   study	   follow-­‐up.	   The	   number	   of	   patients	   who	   needed	  hospitalization	   was	   significantly	   increased	   in	   the	   presence	   of	   bactDNA	   at	   baseline	  (16.3%	  vs	  1.6	  %	   in	  patients	  without	  bactDNA	  at	  baseline,	  p<0.001).	  Five	  patients	  with	  bactDNA	   (5.1%)	   required	   surgery	   in	   the	   following	   six	   months	   (bowel	   resection	   in	   3	  patients	  	  and	  drainage	  of	  perianal	  abscess	  and	  fistulae	  in	  2	  patients)	  whereas	  no	  surgery	  was	  required	   in	   this	   time-­‐frame	   in	   the	  group	  of	  patients	  without	  bactDNA	  at	  baseline.	  Other	  significant	  differences	  in	  the	  6-­‐month	  clinical	  evolution	  between	  patients	  with	  and	  without	   bactDNA	   at	   baseline	   were	   the	   switch	   of	   treatment,	   the	   initiation	   and	   the	  escalation	  of	  anti-­‐TNF	  therapy	  and	  the	  initiation	  of	  steroids	  (Table	  4A).	  	  	  
Among	   analytical	   parameters	   at	   6	   months,	   only	   fecal	   calprotectin	   was	   significantly	  increased	   in	   CD	   patients	   with	   bactDNA	   at	   baseline	   compared	   with	   those	   without	  evidences	   of	   this	   bacterial	   antigen	   in	   blood	   (60.06±98.5	   vs	   151.31±188.98	   ug/g;	  p=0.001)	  (Table	  4A).	  	  Hospitalization,	   the	   switch	   of	   treatment,	   the	   escalation	   of	   anti-­‐TNF	   therapy	   and	   the	  startup	  of	   steroids	  were	  also	  significantly	  different	  between	  patients	  compared	  by	   the	  group	   of	   therapy	   (Table	   4B).	   Any	   of	   the	   analytical	   parameters	   evaluated	   at	   6	  months	  other	  than	  fecal	  calprotectin	  was	  significantly	  different	  between	  CD	  patients	  distributed	  by	  group	  of	  therapy	  (Table	  4B).	  
	  A	   logistic	   regression	   analysis	   was	   performed	   controlling	   by	   all	   baseline	   clinical	   and	  analytical	   variables	   and	   showed	   bactDNA	   as	   the	   only	   significant	   predictive	   factor	   of	  hospitalization	   (OR	  11.9	   [3.4-­‐42.3];	  p<0.001)	   and	   the	   startup	  of	   steroids	   (OR	  8.5	   [2.7-­‐27.1];	  p<0.001)	  at	  six	  months.	  BactDNA	  (OR	  3.5	  [1.6-­‐7.7];	  p=0.002)	  and	  active	  smoking	  habit	   (OR	   2.7	   [1.2-­‐6.4];	   p=0.02)	   were	   both	   significant	   predictive	   factors	   of	   switch	   of	  treatment.	  	  
	  
Gut	  bactDNA	  translocation	  does	  not	  correlate	  with	  endoscopic	  findings	  of	  mucosal	  lesion.	  Colonoscopies	  in	  the	  previous	  month	  to	  admission	  were	  available	  from	  109	  out	  of	  288	  CD	   patients	   (38%)	   included	   in	   the	   study.	   Of	   those,	   54	   patients	   (49.5%)	   presented	  evidences	  of	  	  mucosal	  lesions.	  Table	  5	  details	  their	  distribution	  in	  patients	  according	  to	  bactDNA	  presence	  in	  blood,	  NOD2	  genotype	  and	  group	  of	  therapy.	  As	  can	  be	  observed,	  no	   significant	   differences	   were	   found	   between	   patients	   in	   any	   case.	   Of	   interest,	   no	  relationship	   could	   be	   established	   between	   mucosal	   lesions	   and	   the	   translocation	   of	  bactDNA	   fragments	   into	   blood.	   In	   the	   Cox	   proportional	   hazards	   multiple	   regression	  analysis,	  bactDNA	  (HR	  7.24	  [2.33-­‐22.51];	  p=0.001)	  and	  the	  group	  of	  therapy	   	  (HR	  7.06	  [1.42-­‐35.03];	   p=0.017)	   remained	   independently	   significant,	   Endoscopic	   evidences	   at	  baseline	  of	  mucosal	  lesions	  were	  associated	  with	  higher	  relapse	  rates	  than	  evidences	  of	  no	   lesions,	   although	   this	   difference	   in	   the	   survival	   analysis	   was	   not	   statistically	  significant	   (HR	   1.72	   [0.62-­‐4.73];	   p=0.282)	   (Supplementary	   Figure	   1).	   The	   rest	   of	  complications	  studied	  was	  not	  statistically	  different,	  either.	  	  
The	  probability	  of	  relapse	   in	  bactDNA-­‐positive	  was	  higher	   in	  patients	  with	  endoscopic	  evidence	   of	   mucosal	   lesions	   compared	   with	   no	   lesions	   (8/15	   [53%]	   vs	   4/18	   [22%];	  p=0.08).	   This	   difference	  did	  not	   reach	   statistical	   significance	  probably	  due	   to	   reduced	  sample	  size	  of	  the	  resultant	  subgroups.	  	  	  None	   of	   the	   analytical	   parameters	   evaluated	   at	   6	   months	   were	   statistically	   different	  according	  to	  patients’	  distribution	  by	  endoscopic	  evidence	  of	  mucosal	  lesions	  (data	  not	  shown).	  	  
Gut	   bactDNA	   translocation	   regulates	   serum	   cytokine	   and	   free	   anti-­‐TNF	   levels	   in	   CD	  
patients.	  Serum	  levels	  of	  pro-­‐inflammatory	  cytokines	  were	  measured	  at	  baseline	   in	  all	   included	  patients.	  The	  presence	  of	  bactDNA	   in	  blood	  and	  a	  variant	  NOD2	  genotype	  significantly	  increased	  TNF-­‐alpha	  compared	  with	  levels	  in	  patients	  without	  bactDNA	  (Figure	  2A)	  or	  with	  a	  wild-­‐type	  NOD2	  genotype	  (Figure	  2B),	  respectively.	  The	  distribution	  of	  patients	  by	  group	  of	  therapy	  did	  not	  reveal	  any	  significant	  differences	  in	  serum	  TNF-­‐alpha	  levels	  (Figure	  2C).	  	  Serum	  TNF-­‐alpha	  levels	  were	  independently	  evaluated	  in	  patients	  on	  anti-­‐TNF	  therapy,	  either	  alone	  or	  combined	  with	  IS,	  together	  with	  free	  anti-­‐TNF	  levels.	  The	  distribution	  of	  patients	  by	  the	  presence	  of	  bactDNA	  and	  the	  NOD2	  genotype	  revealed	  that	  the	  highest	  TNF-­‐alpha	  and	  the	  lowest	  anti-­‐TNF-­‐alpha	  levels	  were	  present	  in	  patients	  with	  bactDNA	  and	  a	  variant	  NOD2	  genotype	  (Figure	  2D	  and	  2E).	  Of	  interest,	  five	  patients	  showed	  anti-­‐drug	   antibodies	   in	   blood,	   2	   on	   anti-­‐TNF	   monotherapy	   and	   3	   on	   anti-­‐TNF	   and	   IS	  combined	  therapy,	  and	  were	  not	   included	   in	   these	   figures.	  Eighteen	  patients	  out	  of	  81	  (22.2%)	   were	   on	   intensified	   anti-­‐TNF	   therapy.	   Need	   for	   intensification	   was	   clearly	  related	  with	   the	  presence	  of	  bactDNA	   (15	  out	  of	  18	  patients,	   83.3%).	  A	  variant	  NOD2	  genotype	   was	   present	   in	   2	   intensified	   patients	   without	   bactDNA	   (4.2%)	   and12	  intensified	  patients	  with	  bactDNA	  (35.3%,	  p=0.01).	  Figure	  2F	  shows	  the	  percentage	  of	  patients	   on	   intensified	   anti-­‐TNF	   therapy	   in	   each	   subgroup	   of	   patients.	   A	   negative	  correlation	  was	  established	  between	  TNF-­‐alpha	  and	  free	  anti-­‐TNF-­‐alpha	  in	  blood	  of	  the	  overall	  series	  of	  CD	  patients	  on	  anti-­‐TNF	  therapy	  (r=-­‐0.57;	  p<0.001).	  	  	  
The	   serum	   levels	   of	   IL-­‐6,	   IFN-­‐gamma	   and	   IL-­‐12	   in	   patients	   either	   distributed	   by	  bactDNA,	  NOD2	   genotype	   or	   group	   of	   therapy	   are	   detailed	   in	   Supplementary	  Table	   2.	  Also,	   no	   differences	   in	   serum	   levels	   of	   any	   of	   the	   pro-­‐inflammatory	   cytokines	   were	  observed	   in	   patients	   distributed	   by	   endoscopic	   findings	   of	   mucosal	   lesion	   or	   healing	  (data	  not	  shown).	  	  
Discussion	  	  This	  prospective,	  observational	  study	  was	  designed	  to	  evaluate	  the	  clinical	  implications	  in	  the	  short-­‐term	  of	  circulating	  bactDNA	  fragments	  in	  blood	  of	  CD	  patients	  in	  remission.	  Results	  show	  that	  CD	  patients	  with	  bactDNA	  are	  at	  significantly	  increased	  risk	  of	  relapse	  at	  6	  months.	  Other	  clinical	  complications	  such	  as	  the	  need	  for	  hospitalization,	  switch	  of	  treatment,	  startup	  of	  steroids	  or	  surgery	  are	  also	  significantly	  increased	  in	  the	  group	  of	  CD	   patients	   with	   bactDNA	   fragments	   in	   blood	   compared	   with	   those	   showing	   no	  evidence	   of	   this	   bacterial	   antigen	   type	   in	   the	   circulation.	   These	   results	   show	   the	  relevance	   of	   identifying	   circulating	   bacterial	   antigens	   in	   CD	  patients	   and	  may	  provide	  the	   rationale	   for	   a	   distinct	   therapeutic	   management	   to	   maintain	   remission	   in	   the	  subgroup	  of	  bactDNA-­‐positive	  CD	  patients.	  	  	  Different	   factors	   have	   been	   associated	  with	   a	   disabling	   course	   of	   CD	   in	   the	   following	  years,	  as	  disease	  behavior,	  the	  age	  of	  onset	  and	  the	  initial	  requirement	  of	  steroids	  32.	  The	  chronic	   inflammatory	  condition	  that	  characterizes	  CD	  is	  recurrently	  altered	  by	  disease	  flare-­‐ups	  and,	  eventually,	  irreversible	  lesions	  that	  may	  result	  in	  resection	  surgery.	  Some	  of	  the	  key	  elements	  that	  have	  been	  associated	  with	  disease	  exacerbation	  are	  the	  use	  of	  non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  33,	  an	  active	  smoking	  habit	  34,	  and	  non-­‐compliance	  with	  medication	   35,	  36.	   Even	   the	   emotional	   stress	   has	   been	   suggested	   as	   a	  trigger	  of	  flare	  by	  CD	  patients	  37,	  38.	  	  The	  etiology	  of	  CD	  includes,	  among	  other	  factors,	  the	  inadequate	  interaction	  between	  the	  host	  and	  intestinal	  microorganisms	  3,	  5,	  6,	  as	  well	  as	  a	  partial	  genetic	  predisposition	  mainly	  derived,	  but	  not	  exclusively,	  from	  allelic	  variants	  of	  the	  NOD2	  gene	  21,	  39,	  40.	  However,	  no	  studies	  were	  available	  regarding	  the	  evaluation	  of	  either	  bacterial	  translocating	  antigens	  or	  variant	  NOD2	  genotypes	  on	  the	  risk	  of	  disease	  relapse	  in	  the	  short-­‐term	  in	  CD	  patients.	  	  	  We	  have	  described	   in	   the	  past	   the	   translocation	  of	  bactDNA	   into	  blood	  of	  CD	  patients,	  and	   also	   the	   partial	   genetic	   influence	   of	   variant	   NOD2	   genotypes	   on	   an	   impaired	  immune	  response	  in	  CD	  patients	  1,	  8,	  41.	  In	  this	  study,	  we	  evaluated	  the	  effect	  of	  bactDNA	  translocation	  and	  NOD2	  genotype	  on	  relapse	  at	  six	  month	   in	  CD	  patients	   in	  remission.	  As	   can	   be	   observed	   in	   Table	   3,	   bactDNA	   translocation	   constituted	   a	   significant	  independent	  risk	  factor	  of	  flare	  in	  the	  multivariate	  survival	  analysis,	  whereas	  the	  variant	  
NOD2	   genotype	   did	   not.	   BactDNA	  had	   been	   reported	   to	   contribute	   to	   perpetuation	   of	  sustained	   intestinal	   inflammation	   4,	  which	  may	   favor	   relapse	   in	   CD	  patients.	   This	   fact	  could	  account	  for	  the	  association	  observed	  herein	  between	  bactDNA	  and	  the	  increased	  risk	  of	  flare.	  Along	  with	  bactDNA	  translocation,	  the	  distribution	  of	  CD	  patients	  by	  group	  of	   therapy	   was	   also	   shown	   as	   an	   independent	   risk	   factor	   of	   relapse	   at	   six	   months.	  Patients	   on	   combined	   therapy	  with	   IS	   and	   anti-­‐TNF	  were	   at	   higher	   risk	   than	  patients	  without	  treatment	  or	  those	  with	  mesalazine.	   	  This	  is	  an	  expected	  result,	  as	  patients	  on	  heavier	   therapies	   are	   more	   likely	   identifying	   more	   aggressive	   disease	   phenotypes,	  which	  obviously	  account	  for	  relapse.	  	  	  The	  endoscopic	  evidence	  of	  mucosal	  lesion	  was	  evaluated	  as	  predictive	  factor	  of	  relapse	  at	   6	   months	   in	   the	   subgroup	   of	   patients	   with	   available	   colonoscopy	   in	   the	   previous	  month	  to	  admission.	  The	  presence	  of	  mucosal	  lesions	  almost	  doubled	  the	  risk	  of	  relapse	  but	   this	   increment	   was	   not	   statistically	   significant,	   probably	   as	   a	   consequence	   of	   an	  unpowered	  sample	  size.	  However,	  in	  this	  same	  subgroup	  of	  patients,	  bactDNA	  presence	  and	  the	  group	  of	  therapy	  remained	  as	  independent	  and	  significant	  risk	  factors	  of	  flare	  at	  six	  months.	   Interestingly,	   the	   relapse	   rate	  among	  bactDNA-­‐positive	  patients	  was	  more	  frequent	  in	  those	  with	  mucosal	  lessions	  (53%	  vs	  22%),	  suggesting	  that,	  despite	  no	  lesion	  is	  needed	  for	  bactDNA	  to	  translocate,	  the	  presence	  of	  mucosal	  aphtous	  lesions	  or	  ulcers	  may	  sinergistically	  act	  with	  bactDNA	  as	  inflammatory	  triggers	  conducting	  to	  relapse.	  On	  the	   other	   hand,	   although	   mucosal	   healing	   has	   been	   associated	   with	   reduced	  hospitalization	  42	  and	  surgery	  rates	  43	  or	  maintenance	  of	  clinical	  remission	  44,	  we	  do	  not	  find	  differences	  in	  these	  complications	  either	  compared	  with	  patients	  showing	  mucosal	  lesions.	  The	  shorter	  follow-­‐up	  period	  compared	  with	  those	  studies	  may	  account	  for	  the	  discrepancies.	  	  	  	  Besides	  risk	  of	   flare	  at	  six	  months,	   the	  presence	  of	  bactDNA	  in	  blood	  of	  CD	  patients	   in	  remission	   was	   also	   significantly	   associated	   with	   an	   increased	   risk	   of	   hospitalization,	  surgery,	  switch	  of	  treatment,	  anti-­‐TNF	  intensification,	  startup	  of	  steroids	  and	  increased	  fecal	   calprotectin	   levels	   in	   this	   time-­‐frame	   (Table	   4A).	   These	   results	   clearly	   identify	  bactDNA	   as	   a	  marker	   of	   relevant	   disease	   complications	   that	   not	   only	   affects	   patients’	  welfare	  but	  also	  could	  have	  an	  economic	  impact	  on	  the	  health	  system.	  	  	  
From	   an	   immunologic	   point	   of	   view,	   bacterial	   elements	   such	   as	   DNA	   are	   known	   to	  induce	   an	   increased	   inflammation	   through	   activation	   of	   the	  NF-­‐KB	   signaling	   pathway	  after	  host	  recognition	  by	  specific	  receptors	   in	  different	   immune	  cell	   types	  9,	  16.	  The	  gut	  epithelial	  barrier	  plays	  a	  crucial	   role	   in	  regulating	   the	  uptake	  of	   luminal	  antigens.	  The	  episodic	   translocation	   of	   bactDNA	   may	   be	   suggesting	   either	   a	   dysfunction	   in	   the	  epithelial	   cell	   layer	   or	   an	   intestinal	   bacterial	   overgrowth.	   In	   fact,	   inflammatory	   bowel	  diseases	  have	  been	  associated	  with	  an	  altered	  gut	  microbiota	  composition	  45.	  Anyhow,	  results	   described	   herein	   showing	   the	   presence	   of	   bactDNA	   in	   CD	   patients	   regardless	  endoscopic	   evidences	   of	  mucosal	   lesions	   suggests	   first,	   the	   relative	   ease	   for	   bacterial	  fragments	   to	   cross	   the	   gut	   barrier.	   In	   fact,	   bacterial	   translocation	   is	   considered	   as	   a	  physiologic,	   naturally	   occurring	   event	   in	   healthy	   conditions	   that	   may	   turn	   into	  “pathological”	   under	   increased	   bacterial	   pressure.	   Therefore,	   and	   secondly,	   results	  suggest	   the	  utmost	   relevance	  of	   the	   immune	   system	   to	   counteract	   these	   translocation	  episodes.	  In	  this	  regard,	  the	  NOD2	  genotype	  becomes	  relevant	  and,	  as	  shown	  in	  Figure	  2D,	   a	   variant	   NOD2	   genotype	   is	   associated	   with	   an	   exacerbated	   TNF-­‐alpha	   response	  against	  bactDNA.	  	  	  The	   results	   in	   the	   inflammatory	   soluble	   mediators	   are	   particularly	   relevant	   in	   the	  subgroup	   of	   patients	   on	   anti-­‐TNF	   therapy,	   which	   are	   reflected	   in	   an	   increased	   drug	  consumption	   (Figure	   2E)	   and	   an	   increased	   rate	   of	   intensified	   anti-­‐TNF	   therapy	   in	  patients	  with	  bactDNA	  and	  a	  variant	  NOD2	  genotype	  (Figure	  2F).	  These	  findings	  are	  in	  line	   with	   previous	   reported	   results	   on	   the	   effect	   of	   variant	   NOD2	   genotypes	   and	  bactDNA	   translocation	   on	   the	   efficacy	   of	   anti-­‐TNF	   therapies	   8.	   The	   increased	   Th1	  response,	   as	  a	   consequence	  of	  bactDNA	   translocation	  and	  an	   impaired	  NOD2	   function,	  might	  perpetuate	   the	  progression	  of	   the	  disease	   in	   this	   subgroup	  of	  patients,	  who	  are	  not	   adequately	   responding	   to	   the	   therapy	   schedule	   and	   might	   benefit	   from	   different	  strategies	   to	   prevent	   immunological	   derangements	   that	   may	   favor	   relapse.	   In	   fact,	  different	   studies	  have	  demonstrated	   that	   standard	   therapy	  schedules	  do	  not	   show	  the	  same	  efficacy	  in	  all	  CD	  patients,	  and	  efforts	  are	  needed	  to	   identify	  subgroups	  that	  may	  benefit	   from	   alternative,	  more	   aggressive	   early	   treatments	   to	   control	   and	   change	   the	  course	  of	  the	  disease	  46-­‐48.	  	  
	  
Although	  we	   acknowledge	   the	   limitations	  derived	   from	  an	  observational	   study	  design	  and	   the	  reduced	  number	  of	  patients	   regarding	   the	   inflammatory	  response	   in	  anti-­‐TNF	  therapy	  groups,	  the	  results	  obtained	  on	  the	  effect	  of	  bactDNA	  on	  the	  primary	  study	  end-­‐point	  and	  clinical	  complications	  considered	  at	  6	  months	  offer	  solid	  evidence	  	  implicating	  bactDNA	  as	  a	  relevant	  factor	  inducing	  complications	  in	  CD.	  	  	  	  In	  summary,	  the	  present	  study	  identifies	  bactDNA	  translocation	  as	  an	  independent	  risk	  factor	   of	   relapse	   in	   the	   short-­‐term	   in	   CD	   patients	   in	   remission.	   The	   presence	   of	   this	  bacterial	  antigen	  is	  also	   independently	  associated	  with	  a	  significantly	   increased	  risk	  of	  other	   complications	   such	   as	   of	   hospitalization,	   switch	   of	   treatment	   or	   the	   startup	   of	  steroids.	   The	   increased	   inflammatory	   response	   to	   bactDNA	   translocation,	   particularly	  compromised	  in	  patients	  with	  a	  variant	  NOD2	  genotype,	  is	  likely	  identifying	  a	  subgroup	  of	  CD	  patients	  susceptible	  of	  more	  aggressive	  early	  therapeutic	  approaches.	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Table	  1.	  Patients’	  characteristics.	  	  
	  	  	  	  	  	  
P value
Age (years) 42 ± 15 42 ± 15 43 ± 14 0.61
Weight (Kg) 70.65 ± 14.71 71.05 ± 12.80 69.88 ± 17.91 0.16
Gender (male/female), n (%) 0.76
Smoking habit (yes / no / ex), n (%) 0.34
Disease duration (months) 115,13 ± 114,49 114.55 ± 126.92 116.26 ± 85.66 0.29
Resection, n (%) 0.28
CDAI 62.64 ± 33.14 62.08 ± 33.09 63.74 ± 33.45 0.68
Montreal A (age of onset), n (%)
          A1 (<=16)
          A2 (17-40)
          A3 (>40)
Montreal L (location), n (%)
          L1
          L2
          L3
          L4
Montreal B (behavior), n (%)
          B1 (non-stricturing, non-penetrating)
          B1p (non-stricturing, non-penetrating,           
penetrating perianal disease)
          B2 (stricturing)
          B2p (stricturing, perianal disease associated)
          B3 (penetrating)
          B3p (penetrating, penetrating perianal disease)
Therapy, n (%)
          Mesalazine
          Azathioprine
          Metotrexate
          Mesalazine and Azathioprine
          Mesalazine and Steroids
          Azathioprine + Steroids
          Metotrexate + Steroids
          Infliximab
          Adalimumab
          Infliximab + Azathioprine
          Adalimumab + Azathioprine
          Infliximab + Steroids
          Adalimumab + Steroids
          Infliximab + Metotrexate
          Infliximab + Azathioprine + Steroids
          No therapy
Groups of therapy, n (%)
          No IS / no anti-TNF
          IS
          Anti-TNF
          IS + anti-TNF
CRP (mg/dL) 0.58 ± 1.11 0.59 ± 1.09 0.57 ± 1.17 0.82
Fecal Calprotectin (ug/g) 52.35 ± 35.73 54.95 ± 45.02 49.80 ± 23.65 0.12
Haemoglobin (g/dL) 13.93 ± 2.37 13.76 ± 1.49 14.26 ± 3.48 0.22
ESR (mm) 19.2 ± 15.8 18.8 ± 15.3 19.7 ± 15.5 0.15
Albumin (g/dL) 4.13 ± 4.62 4.11 ± 4.61 4.13 ± 4.51 0.53
Total WBCs (mm3) 6880.5 ± 2648.2 6721.4 ± 2579.4 7186.2 ± 2765.2 0.13
Temperature (ºC) 36.07 ± 0.22 36.05 ± 0.17 36.12 ± 0.31 0.18





































































72 (37.9%) / 80 (42.1%) /     
38 (20%)
50 (51.5%) / 48 (48.5%)
43 (43.8%) / 30 (30.6%) / 
25 (25.5%)
51 (26.8%) 20 (20.4%)
10 (5.3%) 6 (6.1%)
153 (53.3%) / 134 




BactDNA-positive      
patients (n=98)
All patients                                                
(n=288)
All values shown as mean ± SD or percentage. P values correspond to he comparison between bactDNA-negative vs bactDNA-positive patients. CDAI: Crohn's Disease 





































Table	  2.	  Bacterial	  DNA	  species	  identification	  in	  CD	  patients.	  	  	  	  
	  	  	  	  
Bacterial DNA identification Patients n (% of bactDNA+ patients)
Concentration of amplified 
bactDNA fragments (ng/uL)
Family /                    
(gram staining)
Patients n (% of 
bactDNA+ 
patients)
Escherichia coli 38 (38.77%) 28.2 ± 12.3
Klebsiella pneumoniae 13 (13.26%) 26.5 ± 10.8
Klebsiella oxytoca 1 (1.02%) 16.5
Bacteroides intestinalis 5 (5.10%) 30.6 ± 15.1
Bacteroides uniformis 2 (2.04%) 21.8 ± 6.1
Bacteroides fragilis 1 (1.02%) 25.1
Bacteroides faecis 1 (1.02%) 30.6
Proteus vulgaris 2 (2.04%) 18.4 ± 8.4
Proteus mirabilis 1 (1.02%) 20.6
Proteus morganii 1 (1.02%) 20.8
Enterobacter cloacae 3 (3.06%) 33.4 ± 9.8
Enterobacter aerogenes 1 (1.02%) 22.8
Shigella flexneri 2 (2.04%) 27.1 ± 7.2
Shigella sonnei 1 (1.02%) 23.2
Citrobacter freundi 2 (2.04%) 22.7 ± 9.4
Morganella morganii 1 (1.02%) 28.6
Serratia marcescens 1 (1.02%) 31.4
Staphylococcus aureus 8 (8.16%) 31.4 ± 8.5 Staphylococcaceae          (gram-positive) 8 (8.2%)
Enterococcus faecalis 7 (7.14%) 22.4 ± 10.5 Enterococcaceae              (gram-positive) 7 (7.1%)
Streptococcus pneumoniae 3 (3.06%) 27.4 ± 6.6
Streptococcus pyogenes 3 (3.06%) 32.4 ± 10.4
Streptococcus agalactiae 1 (1.02%) 26.2
Enterobacteriaceae                
(gram-negative)




Table	  3.	  Univariate	  and	  multivariate	  survival	  analyses	  of	  relapse	  at	  6	  months.	  	  	  	  
	  	  	  	  
Patients who relapse n (%) P value (chi square) Mean of survival (95% CI) Log Rank test P value
yes 32 / 98 (32.6%) 5.24 (4.92 - 5.55)
no 8 / 190 (4.2%) 5.94 (5.88 - 6.00)
no IS / no anti-TNF 5 / 78 (6.4%) 5.86 (5.70 - 6.02)
IS 16 / 129 (12.4%) 5.66 (5.46 - 5.86) 0.165
anti-TNF 9 / 50 (18%) 5.78 (5.57 - 5.99) 0.045
IS + anti-TNF 10 / 30 (33.3%) 5.33 (4.75 - 5.91) <0.001
wild type 24 / 174 (13.8%) 5.69 (5.53 - 5.84)
variant 16 / 114 (14%) 5.72 (5.52 - 5.92)
Bacterial DNA (yes / no)
IS: immunosuppressor; CI: confidence interval
Univariate Survival Analysis at 6 months






2.06 (0.75 - 5.61)




anti-TNF (vs no IS / no anti-TNF)
IS (vs no IS / no anti-TNF)
Group of therapy
0.1692.16 (0.72 - 6.45)
Hazard ratio (95% CI) P value
IS + anti-TNF (vs no IS / no anti-TNF) 0.0025.43 (1.86 - 15.89)
Table	  4.	  Clinical	  complications	  	  and	  analytical	  parameters	  at	  6	  months.	  	  	  A)	  Patients	  distributed	  by	  gut	  bacterial	  DNA	  translocation	  in	  blood	  	  
	  	  	  B)	  Patients	  distributed	  by	  group	  of	  therapy	  	  






Hospitalization, n (%) <0.001
Surgery, n (%) 0.003
Switch of treatment, n (%) 0.005
Anti-TNF startup, n (%) 0.018
Anti-TNF escalation, n (%) 0.008
Anti-TNF switch, n (%) 0.830
Steroids startup, n (%) <0.001
Azathioprine startup, n (%) 0.302
CRP (mg/dL) 0.75 ± 2.01 0.87 ± 1.52 0.623
Calprotectin (ug/g) 60.06 ± 98.5 151.35 ± 188.98 0.001
Haemoglobin (g/dL) 13.73 ± 1.45 13.86 ± 1.47 0.457
ESR 6 (mm) 16.47 ± 13.56 15.94 ± 12.08 0.780
Albumin (g/dL) 4.08 ± 0.54 4.06 ± 0.45 0.868
Total WBCs (mm3) 6952.45 ± 3607.85 8411.45 ± 11132.86 0.102





Number of flares 0.549
BactDNA-positive                    
at baseline (n=98)























Hospitalization, n (%) <0.001
Surgery, n (%) 0.399
Switch of treatment, n (%) 0.005
Anti-TNF startup, n (%) 0.180
Anti-TNF escalation, n (%) 0.008
Anti-TNF switch, n (%) 0.830
Steroids startup, n (%) <0.001
Azathioprine startup, n (%) 0.102
CRP (mg/dL) 0.68 ± 1,44 0.67 ± 1.47 1.23 ± 3.02 0.89 ± 1.55 0.309
Calprotectin (ug/g) 61.78 ± 77.24 76.29 ± 124.24 116.35 ± 183.43 149.47 ± 183.26 0.026
Haemoglobin (g/dL) 13.69 ± 1.60 13.89 ± 1.35 13.72 ± 1.37 13.59 ± 1.68 0.637
ESR (mm) 15.38 ± 13.60 15.20 ± 11.23 17.42 ± 14.96 21.24 ± 15.21 0.190
Albumin (g/dL) 4.08 ± 0.40 4.14 ± 0.55 4.07 ± 0.55 3.84 ± 0.44 0.071
Total WBCs (mm3) 8473.51 ± 12356.47 6460.83 ± 3735.95 7989.28 ± 2782.07 8195.17 ± 4184.48 0.198
CRP: C-reactive protein; ESR: erytrocyte sedimentation rate; WBC: white blood cells.
5 (6.4%) 1 (0.7%) - -
Number of flares 0.549
no IS / no anti-TNF                  
at baseline (n=78)
IS                                             
at baseline (n=129)
anti-TNF                                 
at baseline (n=50)






































Table	  5.	  Distribution	  of	  study	  variables	  and	  complications	  at	  6	  months	  in	  patients	  with	  colonoscopy	  at	  admission.	  	  	  
	  	  	  
P value
BactDNA, n (%) (no / yes) 0.632
NOD2 genotype, n (%) (wt / variant) 0.289
Group of therapy, n (%)




Calprotectin (ug/g) 31.86 ± 16.58 55.06 ± 28.90 42.75 ± 24.83 0.341
Relapse at 6 months (no / yes) 0.561
Hospitalization at 6 months (no / yes) 0.952
Surgery at 6 months (no / yes) 0.201
Switch of treatment at 6 months (no / yes) 0.593
Calprotectin at 6 months (ug/g) 97.60 ± 165.68 86.32 ± 120-04 107.50 ± 167.78 0.524
bactDNA: bacterial DNA; wt: wild type; IS: immunosuppressor
50 (100%) / 0 38 (95%) / 2 (5%) 13 (100%) / 0
46 (92%) / 4 (8%) 32 (80%) / 8 (20%) 11 (84.6%) / 2 (15.4%)
44 (88%) / 6 (12%) 33 (82.5%) / 7 (17.5%) 10 (77%) / 3 (23%)
47 (94%) / 3 (6%) 37 (92.5%) / 3 (7.5%) 12 (92.3%) / 1 (7.7%)
0.56523 (46%) 15 (37.5%) 6 (46.2%)
10 (25%)7 (14%) 2 (15.4%)
9 (18%) 3 (7.5%) 1 (7.7%)
22 (44%) / 28 (66%) 13 (32.5%) / 27 ( 67.5%) 3 (23%) / 7 (77%)
11 (22%) 12 (30%) 4 (30.7%)
No lessions                     
at baseline (n=50)
Aphtous lessions                               
at baseline (n=40)
Ulcers                            
at baseline (n=13)
32 (64%) / 18 (36%) 28 (70%) / 12 (30%) 10 (77%) / 3 (23%)
Figure	  legends.	  	  
Figure	  1.	  	  Overall	  survival	  Kaplan-­‐Meier	  curves	  at	  6	  months	  in	  CD	  patients	  according	  to	  baseline	  bactDNA	  translocation	  (A)	  and	  group	  of	  therapy	  (B).	  	  BactDNA:	  bacterial	  DNA;	  IS:	  immunosuppressor.	  	  	  
Figure	   2.	   Soluble	   inflammatory	   response	   in	   CD	  patients	   in	   remission.	  A)	   Serum	  TNF-­‐alpha	   levels	   in	   CD	   patients	   distributed	   by	   the	   presence	   of	   bactDNA	   translocation	   in	  blood.	  B)	  Serum	  TNF-­‐alpha	  levels	   in	  CD	  patients	  distributed	  by	  the	  NOD2	  genotype.	  C)	  Serum	  TNF-­‐alpha	   levels	   in	  CD	  patients	  distributed	  by	   the	   group	  of	   therapy.	  D)	   Serum	  TNF-­‐alpha	  levels	  in	  CD	  patients	  on	  anti-­‐TNF	  therapy	  distributed	  by	  the	  combination	  of	  bactDNA	   translocation	  and	  NOD2	  genotype.	  E)	  Serum	   free	  anti-­‐TNF-­‐alpha	   levels	   in	  CD	  patients	  on	  anti-­‐TNF	  therapy	  distributed	  by	  the	  combination	  of	  bactDNA	  translocation	  and	   NOD2	   genotype.	   F)	   Percentage	   of	   intensifeid	   CD	   patients	   on	   anti-­‐TNF	   therapy	  distributed	  by	  the	  combination	  of	  bactDNA	  translocation	  and	  NOD2	  genotype.	  *	  p<0.05	  compared	  with	  bactDNA-­‐negative,	  wildtype	  NOD2	  or	  the	  combination	  of	  both;	  $	  p<0.05	  compared	  with	  the	  rest	  of	  groups.	  BactDNA:	  bacterial	  DNA;	  IS:	  immunosuppressor.	  	  	  	  
